The company said that key drugs such as Cymbalta and Alimta had boosted sales in the second quarter, but results for the first six months of 2007 were affected by the acquisitions of ICOS, Hypnion, and Ivy. For the second quarter, the US drug maker reported a sales increase of 20%, to $4. Cymbalta, approved in the US for major depressive disorder, generalized anxiety disorder and for the management of diabetic peripheral neuropathic pain, generated $519. Eli Lilly’s lung cancer drug Alimta also benefited from an increased demand in the quarter, generating sales of $207. We are encouraged by our outlook for the remainder of the year, and we feel confident in again raising our full-year 2007 sales and earnings guidance. read more
Technorati Tags: sales, 2007, drug, earnings, eli, quarter, anxiety disorder news
This entry was posted
on Thursday, July 26th, 2007 at 9:05 am and is filed under Anxiety Disorder News.
You can follow any responses to this entry through the RSS 2.0 feed.
Responses are currently closed, but you can trackback from your own site.
Loading ...
